Evaluation of Diffusion-Weighted MR Imaging at Inclusion in an Active Surveillance Protocol for Low-Risk Prostate Cancer

被引:61
|
作者
Somford, Diederik M. [1 ,2 ]
Hoeks, Caroline M. [3 ]
Hulsbergen-van de Kaa, Christina A. [4 ]
Hambrock, Thomas [3 ]
Futterer, Jurgen J. [3 ]
Witjes, J. Alfred [2 ]
Bangma, Chris H. [5 ]
Vergunst, Henk [1 ]
Smits, Geert A. [6 ]
Oddens, Jorg R. [7 ]
van Oort, Inge M. [2 ]
Barentsz, Jelle O. [3 ]
机构
[1] Canisius Wilhelmina Hosp, Dept Urol, NL-6532 SZ Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6525 ED Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Radiol, NL-6525 ED Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 ED Nijmegen, Netherlands
[5] Erasmus MC, Dept Urol, Rotterdam, Netherlands
[6] Rijnstate Hosp, Dept Urol, Arnhem, Netherlands
[7] Jeroen Bosch Hosp, Dept Urol, sHertogenbosch, Netherlands
关键词
prostatic neoplasms; magnetic resonance imaging; diffusion magnetic resonance imaging; active surveillance; apparent diffusion coefficient; RADICAL-PROSTATECTOMY; GLEASON SCORE; GUIDED BIOPSIES; PATHOLOGICAL FEATURES; HISTOLOGIC GRADE; REPEAT BIOPSY; AGGRESSIVENESS; COEFFICIENT; TUMOR; MEN;
D O I
10.1097/RLI.0b013e31827b711e
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: We aimed to determine whether diffusion-weighted magnetic resonance imaging, by means of the apparent diffusion coefficient (ADC), is able to guide magnetic resonance-guided biopsy in patients fit for active surveillance (AS) and identify patients harboring high-grade Gleason components not suitable for AS. Materials and Methods: Our study was approved by the institutional review board of all participating hospitals, and all patients signed informed consent at inclusion. Fifty-four consecutive patients with low-risk prostate cancer (PCa) underwent multiparametric magnetic resonance imaging (MP-MRI) at inclusion for AS. Cancer-suspicious regions (CSRs) upon 3-T MP-MRI were identified in all patients, and magnetic resonance-guided biopsy was performed in all CSRs to obtain histopathological verification. For all CSRs, a median ADC (mADC) was calculated. Wilcoxon signed ranks and Mann-Whitney tests was performed to detect differences between the groups. We used the area under the receiver operating characteristic curve to evaluate the accuracy of mADC to predict the presence of PCa in a CSR. Level of statistical significance was set at P < 0.05. Results: Mean mADC in the CSRs with PCa was 1.04 x 10(-3) mm(2)/s (SD, 0.29), whereas the CSRs with no PCa displayed a mean mADC of 1.26 x 10(-3) mm(2)/s (SD, 0.25; P < 0.001). Cancer-suspicious regions with a high-grade Gleason component displayed a mean mADC of 0.84 x 10(-3) mm(2)/s (SD, 0.35) vs a mean mADC for the low-grade CSRs of 1.09 x 10(-3) mm(2)/s (SD, 0.25; P < 0.05). A diagnostic accuracy of mADC for predicting the presence of PCa in a CSR with an area under the receiver operating characteristic curve of 0.73 was established (95% confidence interval, 0.61-0.84). Conclusions: Median ADC is able to predict the presence and grade of PCa in CSRs identified by MP-MRI.
引用
收藏
页码:152 / 157
页数:6
相关论文
共 50 条
  • [1] Diffusion-weighted MR imaging of the prostate
    Cornud, F.
    Liberatore, M.
    Beuvon, F.
    Barry, N.
    JOURNAL DE RADIOLOGIE, 2010, 91 (03): : 421 - 430
  • [2] Active surveillance for low-risk prostate cancer - in pursuit of a standardized protocol
    Sosnowski, Roman
    Kamecki, Hubert
    Daneshmand, Siamak
    Rudzinski, Jan K.
    Bjurlin, Marc A.
    Giganti, Francesco
    Roobol, Monique J.
    Klotz, Laurence
    CENTRAL EUROPEAN JOURNAL OF UROLOGY, 2020, 73 (02) : 123 - 126
  • [3] Active surveillance for low-risk prostate cancer
    Klotz, Laurence
    CURRENT OPINION IN UROLOGY, 2017, 27 (03) : 225 - 230
  • [4] Active surveillance for low-risk prostate cancer
    Herlemann, Annika
    Stief, Christian G.
    UROLOGE, 2016, 55 (02): : 269 - 278
  • [5] Active Surveillance for Low-Risk Prostate Cancer
    Laurence Klotz
    Current Urology Reports, 2015, 16
  • [6] Active Surveillance for Low-risk Prostate Cancer
    Mazzucchelli, Roberta
    Nesseris, Ioannis
    Cheng, Liang
    Lopez-Beltran, Antonio
    Montironi, Rodolfo
    Scarpelli, Marina
    ANTICANCER RESEARCH, 2010, 30 (09) : 3683 - 3692
  • [7] Active Surveillance for Low-Risk Prostate Cancer
    Klotz, Laurence
    CURRENT UROLOGY REPORTS, 2015, 16 (04) : 1 - 10
  • [8] Active surveillance for low-risk prostate cancer
    Hadjipavlou, Marios
    Promponas, John
    Madaan, Sanjeev
    JOURNAL OF CLINICAL UROLOGY, 2015, 8 (06) : 420 - 428
  • [9] Active surveillance for low-risk prostate cancer
    Bangma, Chris H.
    Bul, Meelan
    van der Kwast, Theo H.
    Pickles, Tom
    Korfage, Ida J.
    Hoeks, Caroline M.
    Steyerberg, Ewout W.
    Jenster, Guido
    Kattan, Michael W.
    Bellardita, Lara
    Carroll, Peter R.
    Denis, Louis J.
    Parker, Chris
    Roobol, Monique J.
    Emberton, Mark
    Klotz, Laurence H.
    Rannikko, Antti
    Kakehi, Yoshiyuki
    Lane, Janet A.
    Schroder, Fritz H.
    Semjonow, Axel
    Trock, Bruce J.
    Valdagni, Riccardo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 85 (03) : 295 - 302
  • [10] Active Surveillance for Low-Risk Prostate Cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2024, 55 (06)